The levels of norharman are high enough after smoking to affect monoamineoxidase B in platelets

European Journal of Pharmacology

Volumn 441, Issue 1-2, 2002, Pages 115-125

  Rommelspacher, Hans ^a   Meier Henco, Mignon ^a   Smolka, Michael ^a   Kloft, Charlotte ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Harman; Monoamineoxidase; Neuroprotection; Norharman; Parkinson's disease

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; BETA CARBOLINE; ENZYME INHIBITOR; HARMAN; ISOENZYME; TOBACCO SMOKE;

ADULT; ARTICLE; BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME ANALYSIS; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; KINETICS; MALE; NEUROPROTECTION; NORMAL HUMAN; PRIORITY JOURNAL; PROTECTION; SMOKING; THROMBOCYTE; TOBACCO; TURNOVER TIME;

ADULT; BLOOD PLATELETS; HARMINE; HUMANS; KINETICS; MALE; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; SMOKING; TIME FACTORS;

EID: 0037134292     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)01452-8     Document Type: Article

References (48)

1. Cigarette smoking and Parkinson's disease
2. Investigation by Parkinson's disease research group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: Further results of randomised trial and confidential inquiring
3. Monoamine oxidase A and B activities in heavy smokers
4. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: Implication for Parkinson's disease
5. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
6. Elevated norharman plasma levels in alcoholic patients and controls resulting from tobacco smoking
7. Mitochondrial free radical generation, oxidative stress, and aging
8. Epidemiologic approaches to the study of Parkinson's disease etiology
9. Platelets as a model for neurones?
10. The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it
11. Occurrence and partitions of the β-carboline norharman in rat organs
12. Inhibition of monoamine oxidase B in the brains of smokers
13. Smoking and Parkinson's and Alzheimers's disease: Review of the epidemiological studies
14. Smoking and Parkinson's disease, a dose-response relationship
15. Reactive oxygen species and the central nervous system
16. Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease
17. A rapid microfluorometric determination of monoamine oxidase
18. Elevated levels of harman and norharman in cerebrospinal fluid of Parkinsonian patients
19. Potential bioactivated neurotoxicants, N-methylated β-carbolinium ions, are present in human brain
20. 2H]harman binding experiments: I. A reversible and selective radioligand for monoamine oxidase subtype A in the CNS of the rat
21. The influence of smoking on the risk of Alzheimer's disease
22. Cigarette smoking and protection from Prakinson's disease: False association or etiologic clue?
23. Platelet monoamine oxidase: Low activity in cigarette smokers
24. The deamination of dopamine by human brain monoamine oxidase: Specificity for the two forms in seven brain regions
25. Low platelet monoamine oxidase activity in cigarette smokers
26. Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: The Rotterdam Study
27. 3H] β-carboline) in the rat brain
28. Platelets as models for monoaminergic neurons
29. The isolation of harmane and norharmane from tobacco and cigarette smoke
30. Oxidative processes and antioxidative defense mechanisms in the aging brain
31. Is there neuroprotection in Parkinson syndrome?
32. Nigral degeneration in Parkinson's disease in relation to clinical features
33. β-carbolines and tetrahydroisoquinolines: Detection and function in mammals
34. Longitudinal observations of monoamine oxidase B in alcoholics: Differentation of marker characteristics
35. Harman (1-methyl-β-carboline) is a natural inhibitor of monoamine oxidase type A in rats
36. Facilitation of memory by post-trial administration of nicotine: Evidence for an attentional explanation
37. The affects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type
38. β-carbolines in chronic alcoholics undergoing elective tumor resection
39. β-carbolines in chronic alcoholics following trauma
40. Platelets as pharmacologic models for the receptors and biochemistry of monoaminergic neurons
41. Formation of 1-methyl-β-carbolines in rats from their possible carboxylic acid precursor
42. DATATOP: A multicenter controlled trial in early Parkinson's disease
43. Monoamine oxidase-B inhibition: A comparison of in vivo and ex vivo measures of reversible effects
44. Personality traits and platelet monoamine oxidase in tobacco smokers
45. Genetics, drugs and environmental factors in Parkinson's disease. A case-control study
46. Monoamine oxidase B, smoking, and Parkinson's disease
47. Irreversible inhibition of monoamine oxidase by some components of cigarette smoke